BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts

In both HERCULES and GEMINI trials, tolebrutinib reduced the risk of 6-month confirmed disability worsening, especially in participants with at least 4 baseline paramagnetic rim lesions.:

Source: Neurology Read More

Previous PostNeuroVoices: Rosanna Ricafort, MD, on Early Promise of CAR T-Cell Therapy CD19-XT in Multiple Sclerosis
Next PostDMD Community Eyes First Cell Therapy Approval Following FDA’s Acceptance of Deramiocel Submission

BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts

Previous PostNeuroVoices: Rosanna Ricafort, MD, on Early Promise of CAR T-Cell Therapy CD19-XT in Multiple Sclerosis

Next PostDMD Community Eyes First Cell Therapy Approval Following FDA’s Acceptance of Deramiocel Submission

Related Posts

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

Categories